{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:46:51Z","timestamp":1787161611264,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Maria Curie-Sk\u0142odowska University, Lublin, Poland"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.lfs.2016.02.075","type":"journal-article","created":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T05:34:39Z","timestamp":1456205679000},"page":"81-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["SB 334867, a selective orexin receptor type 1 antagonist, elevates seizure threshold in mice"],"prefix":"10.1016","volume":"150","author":[{"given":"Katarzyna","family":"Soca\u0142a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Szuster-Ciesielska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Wla\u017a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2016.02.075_bb0005","doi-asserted-by":"crossref","first-page":"C2","DOI":"10.1152\/ajpcell.00227.2012","article-title":"Physiology of the orexinergic\/hypocretinergic system: a revisit in 2012","volume":"304","author":"Kukkonen","year":"2013","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.lfs.2016.02.075_bb0010","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev-pharmtox-010510-100528","article-title":"Orexin receptors: pharmacology and therapeutic opportunities","volume":"51","author":"Scammell","year":"2011","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.lfs.2016.02.075_bb0015","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/bph.12324","article-title":"Orexin\/hypocretin receptor signalling cascades","volume":"171","author":"Kukkonen","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2016.02.075_bb0020","doi-asserted-by":"crossref","first-page":"9996","DOI":"10.1523\/JNEUROSCI.18-23-09996.1998","article-title":"Neurons containing hypocretin (orexin) project to multiple neuronal systems","volume":"18","author":"Peyron","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.lfs.2016.02.075_bb0025","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1016\/j.bmcl.2015.05.012","article-title":"Recent trends in orexin research-2010 to 2015","volume":"25","author":"Boss","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.lfs.2016.02.075_bb0030","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0893-133X(01)00316-5","article-title":"A commentary on the neurobiology of the hypocretin\/orexin system","volume":"25","author":"Mignot","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.lfs.2016.02.075_bb0035","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10072-013-1495-5","article-title":"Pentylenetetrazol-induced seizures are exacerbated by sleep deprivation through orexin receptor-mediated hippocampal cell proliferation","volume":"35","author":"Ni","year":"2014","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.lfs.2016.02.075_bb0040","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.peptides.2012.06.012","article-title":"Orexins cause epileptic activity","volume":"37","author":"Erken","year":"2012","journal-title":"Peptides"},{"key":"10.1016\/j.lfs.2016.02.075_bb0045","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S0006-8993(99)01131-2","article-title":"Effect of lateral cerebroventricular injection of the appetite-stimulating neuropeptide, orexin and neuropeptide Y, on the various behavioral activities of rats","volume":"821","author":"Ida","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.lfs.2016.02.075_bb0050","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pbb.2015.01.006","article-title":"Hippocampal orexin receptors inactivation reduces PTZ induced seizures of male rats","volume":"130","author":"Goudarzi","year":"2015","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.lfs.2016.02.075_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.npep.2015.04.004","article-title":"Des-acyl ghrelin attenuates pilocarpine-induced limbic seizures via the ghrelin receptor and not the orexin pathway","volume":"51","author":"Portelli","year":"2015","journal-title":"Neuropeptides"},{"key":"10.1016\/j.lfs.2016.02.075_bb0060","doi-asserted-by":"crossref","first-page":"357","DOI":"10.5665\/sleep.5444","article-title":"Orexin receptor antagonism improves sleep and reduces seizures in Kcna1-null mice","volume":"39","author":"Roundtree","year":"2016","journal-title":"Sleep"},{"key":"10.1016\/j.lfs.2016.02.075_bb0065","first-page":"74","article-title":"Orexinergic system and pathophysiology of epilepsy","volume":"188","author":"Doreulee","year":"2010","journal-title":"Georgian Med. News"},{"key":"10.1016\/j.lfs.2016.02.075_bb0070","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.peptides.2013.11.019","article-title":"Orexin-A-induced ERK1\/2 activation reverses impaired spatial learning and memory in pentylenetetrazol-kindled rats via OX1R-mediated hippocampal neurogenesis","volume":"54","author":"Zhao","year":"2014","journal-title":"Peptides"},{"key":"10.1016\/j.lfs.2016.02.075_bb0075","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S1734-1140(12)70940-4","article-title":"Level of S100B protein, neuron specific enolase, orexin A, adiponectin and insulin-like growth factor in serum of pediatric patients suffering from sleep disorders with or without epilepsy","volume":"64","author":"Kaci\u0144ski","year":"2012","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.lfs.2016.02.075_bb0080","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1111\/j.1528-1167.2008.01990.x","article-title":"Decreased cerebrospinal fluid hypocretin-1 (orexin A) in patients after repetitive generalized tonic-clonic seizures","volume":"50","author":"Rejdak","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.lfs.2016.02.075_bb0085","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.bbr.2012.12.064","article-title":"Orexin-1 receptor antagonism fails to reduce anxiety-like behaviour in either plus-maze-naive or plus-maze-experienced mice","volume":"243","author":"Rodgers","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.lfs.2016.02.075_bb0090","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.bbr.2004.07.012","article-title":"Anorexia and weight loss in male rats 24h following single dose treatment with orexin-1 receptor antagonist SB-334867","volume":"157","author":"Ishii","year":"2005","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.lfs.2016.02.075_bb0095","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1523\/JNEUROSCI.5724-09.2010","article-title":"Hypocretins regulate the anxiogenic-like effects of nicotine and induce reinstatement of nicotine-seeking behavior","volume":"30","author":"Plaza-Zabala","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.lfs.2016.02.075_bb0100","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/j.1476-5381.2009.00127.x","article-title":"Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor","volume":"156","author":"Malherbe","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2016.02.075_bb0105","first-page":"1444","article-title":"SB-334867, a selective orexin-1 receptor antagonist, enhances behavioural satiety and blocks the hyperphagic effect of orexin-A in rats","volume":"13","author":"Rodgers","year":"2001","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.lfs.2016.02.075_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/3570549","article-title":"Chemical protection against ionizing radiation. I. Sampling methods for screening compounds in radiation protection studies with mice","volume":"7","author":"Kimball","year":"1957","journal-title":"Radiat. Res."},{"key":"10.1016\/j.lfs.2016.02.075_bb0115","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0960-894X(01)00343-2","article-title":"1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor","volume":"11","author":"Porter","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.lfs.2016.02.075_bb0120","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.bjp.0703953","article-title":"SB-334867-A: the first selective orexin-1 receptor antagonist","volume":"132","author":"Smart","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2016.02.075_bb0125","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/B978-0-444-59489-1.00007-0","article-title":"Multiple roles for orexin\/hypocretin in addiction","volume":"198","author":"Mahler","year":"2012","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.lfs.2016.02.075_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2009.03.025","article-title":"Preclinical assessment of proconvulsant drug activity and its relevance for predicting adverse events in humans","volume":"610","author":"L\u00f6scher","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2016.02.075_bb0135","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1358\/mf.2009.31.2.1338414","article-title":"The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs","volume":"31","author":"Castel-Branco","year":"2009","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"10.1016\/j.lfs.2016.02.075_bb0140","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(01)00302-3","article-title":"Pharmacological characterization of the 6Hz psychomotor seizure model of partial epilepsy","volume":"47","author":"Barton","year":"2001","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.lfs.2016.02.075_bb0145","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.peptides.2012.02.013","article-title":"Orexins increase penicillin-induced epileptic activity","volume":"34","author":"Kortunay","year":"2012","journal-title":"Peptides"},{"key":"10.1016\/j.lfs.2016.02.075_bb0150","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.neuroscience.2004.05.012","article-title":"Orexins\/hypocretins cause sharp wave- and theta-related synaptic plasticity in the hippocampus via glutamatergic, gabaergic, noradrenergic, and cholinergic signaling","volume":"127","author":"Selbach","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.lfs.2016.02.075_bb0155","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1113\/jphysiol.2002.038729","article-title":"Intravenously administered hypocretin-1 alters brain amino acid release: an in vivo microdialysis study in rats","volume":"548","author":"John","year":"2003","journal-title":"J. Physiol."},{"key":"10.1016\/j.lfs.2016.02.075_bb0160","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neuroscience.2011.08.033","article-title":"Aging-related alterations in orexin\/hypocretin modulation of septo-hippocampal amino acid neurotransmission","volume":"195","author":"Stanley","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.lfs.2016.02.075_bb0165","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.nlm.2015.02.001","article-title":"The electrical activity of hippocampal pyramidal neuron is subjected to descending control by the brain orexin\/hypocretin system","volume":"119","author":"Riahi","year":"2015","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.lfs.2016.02.075_bb0170","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.neuropharm.2007.05.027","article-title":"Pretreatment with subeffective doses of Rimonabant attenuates orexigenic actions of orexin A-hypocretin 1","volume":"54","author":"Crespo","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.lfs.2016.02.075_bb0175","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.brainres.2014.11.002","article-title":"Changes and overlapping distribution in the expression of CB1\/OX1-GPCRs in rat hippocampus by kainic acid-induced status epilepticus","volume":"1597","author":"Zhu","year":"2015","journal-title":"Brain Res."},{"key":"10.1016\/j.lfs.2016.02.075_bb0180","doi-asserted-by":"crossref","first-page":"38812","DOI":"10.1074\/jbc.M602494200","article-title":"Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function","volume":"281","author":"Ellis","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2016.02.075_bb0185","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.peptides.2006.11.002","article-title":"The selective orexin 1 receptor antagonist SB-334867-A impairs acquisition and consolidation but not retrieval of spatial memory in Morris water maze","volume":"28","author":"Akbari","year":"2007","journal-title":"Peptides"},{"key":"10.1016\/j.lfs.2016.02.075_bb0190","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.seizure.2011.01.003","article-title":"Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs","volume":"20","author":"L\u00f6scher","year":"2011","journal-title":"Seizure"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320516301254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320516301254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T03:13:33Z","timestamp":1617592413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320516301254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":38,"alternative-id":["S0024320516301254"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2016.02.075","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SB 334867, a selective orexin receptor type 1 antagonist, elevates seizure threshold in mice","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2016.02.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}